07:34 AM EDT, 04/10/2025 (MT Newswires) -- Revive Therapeutics ( RVVTF ) on Thursday said it has been contacted by a U.S. cancer institute to investigate bucillamine's potential as a cancer treatment, particularly for boosting anti-tumor effects in patients with advanced solid tumors.

This evaluation of bucillamine in solid tumors would be integrated into a broader study, supported by funding from the National Institutes of Health and/or other government entities.

The company also said results from its study with an agency of the Canadian Department of National Defense, evaluating bucillamine as a potential treatment for nerve agent exposure, are expected shortly.

"We look forward to collaborating with a top U.S. cancer institute to investigate Bucillamine's potential for solid tumors, confirming its anti-inflammatory and antioxidant effects, since inflammation and oxidative stress are recognized contributors to cancer initiation and growth," said Chief Executive Michael Frank.